香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成生 化科 技集 團 有 限公 司 * （於開曼群島註冊成立的有限公司） （股份代號：00809） 截至 年 月 日止六個月 2023 6 30 中期業績公告 財務摘要 截至6月30日止六個月 2023年 2022年 變動% （未經審核） （未經審核） 收益（百萬港元） 662.5 155.6 325.8 （毛損）毛利（百萬港元） (38.2) 11.7 不適用 除稅前虧損（百萬港元） (130.6) (829.2) 不適用 ...

Debt Restructuring - The debt restructuring plan includes the transfer of loans from four major banks, with the total principal amount owed to Agricultural Bank of China being approximately RMB 1,400,000,000, of which RMB 1,100,000,000 is owed by the group [3]. - The group plans to repurchase the transferred loans for approximately RMB 1,500,000,000 to RMB 1,600,000,000, with discussions still in early stages and no final agreements reached [5]. - The expected completion date for the full repurchase of transferred loans is between the end of 2023 and the first half of 2024 [7]. - The principal amount owed to China Construction Bank is approximately RMB 1,983,500,000, which has been transferred for about RMB 583,600,000 [4]. - The principal amount owed to the Export-Import Bank is approximately RMB 1,184,300,000, transferred for about RMB 356,000,000 [4]. - The group anticipates that the unpaid amount for the repurchased loans will be settled by the end of 2025 [7]. - The group is exploring various funding possibilities to advance the debt restructuring plan with potential investors expressing interest [5]. Loan Details - The total outstanding principal amount of loans as of January 31, 2023, is approximately RMB 1,326,300,000, with RMB 834,800,000 intended to be financed through ongoing business operations and future cash flows [7]. - The group has a remaining land and building value of approximately RMB 524,700,000, which is mortgaged as collateral for the repurchased loans [5]. - The outstanding amount for the repurchased loans is expected to be settled using proceeds from the sale of related properties [5].

Financial Performance - The company recorded a significant increase in net loss for the year due to the absence of one-time debt restructuring gains from the previous year, resulting in a net loss of approximately 1,519.6 million HKD[10]. - The company's consolidated revenue decreased by approximately 50.1% to around HKD 372.3 million, down from HKD 746.6 million in 2021[30]. - The gross profit also saw a significant decline of about 28.5%, amounting to HKD 34.6 million compared to HKD 48.4 million in the previous year[30]. - Other income and gains decreased by approximately 97.8% to about HKD 30.9 million, primarily due to the absence of a one-time debt restructuring gain recorded in 2021[40]. - Losses from Da Cheng Sugar and a non-wholly owned subsidiary amounted to approximately HKD 212.5 million, leading to a loss attributable to non-controlling interests of about HKD 76.5 million[45]. - The group recorded a net loss of approximately HKD 1,519.6 million for the year, compared to a loss of HKD 435.4 million in 2021, resulting in a net liability of approximately HKD 7,787.1 million[85]. Operational Challenges - The company's production activities were disrupted for two months due to pandemic control measures in Shanghai, affecting overall production and logistics[9]. - The upstream facilities were largely non-operational for most of the year, with a production resumption in December 2022[23]. - The global corn production for the 2022/23 season is estimated at 1,151.4 million tons, a decrease from 1,216 million tons in the previous season, impacting the company's upstream corn refining business[15]. - The revenue from the corn sweetener segment decreased by approximately 50.6% to about HKD 359.6 million (2021: HKD 727.3 million), primarily due to a sales volume drop of about 52.2% to approximately 85,000 tons (2021: 178,000 tons)[50]. Strategic Plans and Restructuring - The amino acid production line successfully resumed operations, and the restructuring plan with Da Cheng Sugar Industry is expected to significantly improve the company's financial situation[11]. - The company anticipates that after completing the restructuring plans, its business operations will gradually return to normal, facilitating strategic cooperation with third-party investors[12]. - The management is focused on debt restructuring plans to significantly improve the company's financial situation[27]. - The company plans to sell approximately 47% of its issued share capital in a subsidiary, which will improve its financial condition post-transaction[24]. - The company announced a proposed restructuring of Da Cheng Sugar, including the issuance of convertible bonds totaling RMB 120 million[37]. Market Conditions - Domestic corn production in China for the 2022/23 season is projected to be approximately 277.2 million tons, with consumption expected to be 286.6 million tons[15]. - The international corn price peaked at 818 cents per bushel in April 2022, influenced by the Ukraine war, but fell to 678.5 cents per bushel by the end of 2022[15]. - China's corn price increased to 2,816 RMB per ton by the end of 2022, compared to 2,734 RMB per ton at the end of 2021, due to high prices and economic slowdown[15]. - The average selling price of sweetener products increased, leading to a gross margin growth of 2.8 percentage points to 9.3% from 6.5% in 2021[30]. Cost Management - Sales and distribution costs decreased by 37.5% to approximately HKD 39.7 million, accounting for about 10.7% of the group's revenue[41]. - Administrative expenses decreased by 12.0% to approximately HKD 328.2 million, mainly due to effective cost control measures[42]. - Other expenses decreased by 14.2% to approximately HKD 545.2 million, primarily due to the release of financial guarantee liabilities[43]. - Financial costs decreased by 8.1% to approximately HKD 726.2 million, attributed to agreements reached with creditors[44]. Governance and Management - The company has established a robust mechanism to ensure strong independence of the board, which is reviewed annually for effectiveness[184]. - The audit committee, composed entirely of independent non-executive directors, held three meetings during the year to oversee financial reporting and risk management[174]. - The company has implemented a clear governance structure, including the establishment of various committees to enhance operational efficiency[196]. - The board meets at least four times a year to discuss overall strategy, operational and financial performance, and other significant matters[160]. Human Resources - The group employed approximately 3,500 full-time employees as of December 31, 2022, down from 3,700 in 2021[117]. - Employee costs, including director remuneration, amounted to approximately HKD 274,033,000 in 2022, compared to HKD 272,259,000 in 2021[117]. - The company emphasizes the importance of human resources management as a source of competitive advantage in a volatile environment[117]. - The company recognizes employee contributions and strives to maintain competitive compensation and career development opportunities[117].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：00809） 截至 年 月 日止年度 2022 12 31 全年業績公告 財務概要 2022年 2021年 變動% 收益（百萬港元） 372.3 746.6 (50.1) 毛利（百萬港元） 34.6 48.4 (28.5) 本年度虧損（百萬港元） (1,519.6) (435.4) 不適用 本公司擁有人應佔虧損（百萬港元） (1,443.1) (400.8) 不適用 每股基本虧損（港仙） (16.2) (4.5) 不適用 擬派每股末期股息（港仙） — — 不適用 ...

大 成 生 化 科 技 集 團 有 限 公 司 * Chem Technology Group Company Limited 股份代號：00809 2022 中 期 報 告 ° 匯 供 該 別 目錄 | --- | --- | |------------------------------|-------| | | | | 財務概要 2 | | | 公司資料 3 | | | 致股東簡報 4 | | | 管理層討論及分析 6 | | | 其他資料的披露 16 | | | 簡明綜合財務報表 | | | 簡明綜合損益及其他全面收益表 | 26 | | 簡明綜合財務狀況表 27 | | | 簡明綜合權益變動表 29 | | | 簡明綜合現金流量表 30 | | | 簡明綜合財務報表附註 32 | | 004888 財務概要 | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|----------------- ...

Financial Performance - Revenue for 2021 was HKD 746.6 million, a decrease of 12.1% from HKD 848.9 million in 2020[6] - Gross profit for 2021 was HKD 48.4 million, down 34.7% from HKD 74.1 million in 2020[6] - The company reported a significant annual loss of HKD 435.4 million, a reduction of 82.1% compared to a loss of HKD 2,433.3 million in 2020[12] - EBITDA for the year was approximately HKD 783.6 million[12] - The company's consolidated revenue decreased by 12.1% to approximately HKD 746.6 million, down from HKD 848.9 million in the previous year[33] - The gross profit for the year fell by approximately 34.7% to about HKD 48.4 million, with a gross margin decline of 2.2 percentage points to 6.5%[33] - The company recorded a significant reduction in net loss to approximately HKD 435.4 million, compared to HKD 2,433.3 million in the previous year, and EBITDA improved to about HKD 783.6 million from a loss of HKD 1,229.2 million[34] Production and Operations - The lysine production line remained idle throughout the year due to cash flow constraints, despite rising global lysine prices[16] - The sweetener business experienced a decline in gross profit and margin due to insufficient price increases to cover rising raw material and energy costs[16] - The company suspended most production facilities to avoid cash flow losses amid rising raw material costs and supply chain disruptions[12] - The group plans to resume some upstream production lines at the Xinglongshan plant within the year to improve cash flow and support downstream recovery[18] - The upstream business revenue plummeted by approximately 99.7% to about HKD 800,000, with no sales recorded for corn starch, which previously generated HKD 189.1 million[37] - The company plans to continue observing market conditions and adopt a cautious approach before restarting its biochemicals business, focusing on high-value products[32] - The company aims to maintain competitiveness through internal R&D, debt restructuring, and forming strategic alliances for sustainable development[77] - The company will focus on relocating production facilities and adjusting product mix to respond to market changes while improving operational efficiency through continuous R&D[77] Market Conditions - In 2021, China's GDP grew by 8.1%, but the growth rate showed a quarterly decline, indicating economic downward pressure[18] - The Omicron variant impacted business activities in multiple regions of China in Q1 2022, leading to challenges in the operating environment[18] - The anticipated high corn prices in 2022 are expected to continue posing challenges to the company's operating environment[32] - The operating environment remains challenging due to high raw material costs and geopolitical uncertainties affecting business operations[18] Debt and Financial Management - The company continued to focus on debt restructuring discussions with creditors to return to a healthy development track[12] - The group expects further progress on its debt restructuring plan by the end of 2022, which is crucial for restoring financial stability and growth[20] - The company aims to reduce its financial burden by expediting the collection of properties in Changchun and actively negotiating with banks to advance its debt restructuring plan[36] - The company issued convertible bonds totaling HKD 1,086,279,565, convertible into 4,722,954,631 shares at an initial conversion price of HKD 0.23 per share[54] - As of December 31, 2021, total borrowings decreased by approximately HKD 608,300,000 to about HKD 7,501,300,000, while cash and bank balances decreased by approximately HKD 160,900,000 to about HKD 22,300,000[52] Employee and Governance - The group employed approximately 3,700 full-time employees as of December 31, 2021, down from 4,000 in 2020, highlighting a focus on human resource management as a competitive advantage[79] - Employee compensation includes discretionary bonuses based on performance, aligning employee performance with the company's strategy[79] - The company recognizes the value of employee contributions and strives to maintain competitive compensation and career development opportunities[79] - The board consists of six directors, including two executive directors, one non-executive director, and three independent non-executive directors[97] - The company has achieved a diversity policy for its board members, focusing on gender, education, and professional qualifications[108] Risk Management - The company employs a "three lines of defense" approach to manage operational risks, integrating risk management into business processes[173] - The management is responsible for identifying, understanding, and managing risks to minimize, transfer, and avoid them[173] - Financial risks include liquidity risk due to production suspension, with measures such as property seizure to improve cash flow and attracting potential investors for partial recovery[178] - The company faced compliance risks related to loan agreements, with creditors seeking court orders for settlement, but reached agreements and sought legal advice[178] Corporate Governance - The board of directors is responsible for ensuring compliance with corporate governance policies and practices, having reviewed and monitored adherence to relevant regulations[146] - The company has adopted a code of conduct for directors' securities transactions, ensuring compliance with the relevant listing rules[92] - The audit committee, composed of independent non-executive directors, reviews the financial reporting process, risk management, and internal controls, holding three meetings during the year[136] - The company has established various communication channels with shareholders, including annual and interim reports published on the stock exchange and the company website[156] Environmental, Social, and Governance (ESG) - The company has committed to publishing its Environmental, Social, and Governance (ESG) report annually on its website and the stock exchange[186]

GLOBAL 大成生化科技集團有限公司 * 股份代號：00809 6 g (488) 中期報告 0 a y Bio-Chem Technology Group Company Limited " 僅 供 錄 別 目錄 財務概要2 公司資料3 致股東簡報4 管理層討論及分析7 其他資料的披露18 簡明綜合財務報表 簡明綜合損益及其他全面收益表27 簡明綜合財務狀況表28 簡明綜合權益變動表30 簡明綜合現金流量表31 簡明綜合財務報表附註33 財務概要 | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------|-----------------------------| | | 2021 年 （未經審核） | 截至 6 月 30 ...

GLOBAL 大 成 生 化 科 技 集 團 有 限 公 司 * Bio-Chem Technology Group Company Limited 股份代號：00809 ２０２０ 年 度 報 告 " 僅 供 設 別 目錄 財務概要 2 公司資料 3 致股東簡報 4 管理層討論及分析 7 董事及高級管理層履歷詳情 20 企業管治報告 23 董事會報告 45 獨立核數師報告 61 綜合財務報表 綜合損益及其他全面收益表 64 綜合財務狀況表 65 綜合權益變動表 67 綜合現金流量表 70 綜合財務報表附註 72 五年財務概要 154 財務概要 | --- | --- | --- | --- | |----------------------------------|-----------|-----------|----------| | 財務概要 | 2020 年 | 2019 年 | 變動 % | | | | | | | 收益（百萬港元） | 849 | 4,561 | (81.4) | | 毛利（百萬港元） | 74 | 204 | (63.7) | | 本年度虧損（百萬港元） | (2,433) | ...

GLOBAL 大 成 生 化 科 技 集 團 有 限 公 司 * Bio-Chem Technology Group Company Limited 股份代號：00809 ２０２０ 中 期 報 告 " 僅 供 設 別 目錄 | --- | --- | |------------------------------|-------| | | | | | | | | | | 財務概要 | 2 | | 公司資料 | 3 | | 致股東簡報 | 4 | | 管理層討論及分析 | 7 | | 其他資料的披露 | 19 | | 簡明綜合財務報表 | | | 簡明綜合損益及其他全面收益表 | 29 | | 簡明綜合財務狀況表 | 30 | | 簡明綜合權益變動表 | 32 | | 簡明綜合現金流量表 | 33 | | 簡明綜合財務報表附註 | 35 | 財務概要 截至 6 月 30 日止六個月 | --- | --- | --- | --- | |------------------------|--------------------------|--------------------------|---------- ...

t IIwII Fi & f ii a 年 度 報 告 GLOBAL 大 成 生 化 科 技 集 團 有 限 公 司 * Bio-Chem Technology Group Company Limited 股份代號：00809 " 匯 供 課 別 目錄 公司資料 3 致股東簡報 4 管理層討論及分析 7 董事及高級管理人員履歷詳情 19 綜合財務報表 財務概要 2 企業管治報告 22 董事會報告 43 獨立核數師報告 56 綜合損益及其他全面收益表 59 綜合財務狀況表 60 綜合權益變動表 62 綜合現金流量表 65 綜合財務報表附註 67 五年財務概要 150 財務概要 | --- | --- | --- | --- | |----------------------------------|-----------|-----------|----------| | 財務概要 | 2019 年 | 2018 年 | 變動 % | | | | | | | 收益（百萬港元） | 4,561 | 5,658 | (19.4) | | 毛利（百萬港元） | 204 | 260 | (21.6) | | 本年度虧損 ...